第四季度和2025年全年财务结果及企业更新

Fourth Quarter andFull Year 2025Financial Results &Corporate Update This presentation is for investor relations purposes only - Not for product promotional purposes Agenda Ying Huang, PhDChief Executive Officer Alan BashPresident of CARVYKTI® Carlos SantosChief Financial Officer Forward-looking Statements exchange losses in 2026; the progress of such submissions with the FDA, the EMA and otherregulatory authorities; expected results and timing of clinical trials; Legend Biotech’sexpectations on advancing its pipeline and product portfolio, including TaVec; and the potentialbenefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,”“could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,”“target,” “will,” “would” and similar expressions are intended to identify forward- lookingstatements, although not all forward-looking statements contain these identifying words. Actualresults may differ materially from those indicated by such forward-looking statements as aresult of various important factors. Legend Biotech’s expectations could be affected by, amongother things, uncertainties involved in the development of new pharmaceutical products;unexpected clinical trial results, including as a result of additional analysis of existing clinicaldata or unexpected new clinical data; unexpected regulatory actions or delays, includingrequests for additional safety and/or efficacy data or analysis of data, or government regulationgenerally; unexpected delays as a result of actions undertaken, or failures to act, by our thirdparty partners; uncertainties arising from challenges to Legend Biotech’s patent or otherproprietary intellectual property protection, including the uncertainties involved in the U.S.litigation process; competition in general; government, industry, and general product pricing andother political pressures; as well as the other factors discussed in the “Risk Factors” section ofLegend Biotech’s Annual Report on Form 20-F for the year ended December 31, 2025, filed withthe Securities and Exchange Commission (SEC) on March 10, 2026 and Legend Biotech’s otherfilings with the SEC. This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the“Company”) solely for information purpose and does not contain all relevant informationrelating to the Company. The safety and efficacy of the agents and/or uses under investigation discussed in thispresentation have not been established, except to the extent specifically provided by marketingauthorizations previously received from relevant health authorities. Further, for investigationalagents and/or uses, the Company cannot guarantee health authority approval or that suchagents and/or uses will become commercially available in any country. Certain information contained in this presentation and statements made orally during thispresentation relate to or are based on studies, publications, surveys and other data obtainedfrom third-party sources and Legend Biotech's own internal estimates and research. WhileLegend Biotech believes these third-party sources to be reliable as of the date of thispresentation, it has not independently verified, and makes no representation as to theadequacy, fairness, accuracy or completeness of, any information obtained from third-partysources. While Legend Biotech believes its internal research is reliable, such research has notbeen verified by any independent source. Statements in this presentation about future expectations, plans and prospects, as well as anyother statements regarding matters that are not historical facts, constitute “forward-lookingstatements” within the meaning of The Private Securities Litigation Reform Act of 1995. Should one or more of these risks or uncertainties materialize, or should underlyingassumptions prove incorrect, actual results may vary materially from those described in thispresentation as anticipated, believed, estimated or expected. Any forward-looking statementscontained in this presentation speak only as of the date of this presentation. Legend Biotechspecifically disclaims any obligation to update any forward-looking statement, whether as aresult of new information, future events or otherwise. These statements include, but are not limited to, statements relating to Legend Biotech’sstrategies and objectives; statements relating to CARVYKTI®(ciltacabtagene autoleucel; cilta-cel),including patient population of CARVYKTI®, Legend Biotech’s expectations forCARVYKTI®, including manufacturing expectations for CARVYKTI®; and statements aboutregulatory submissions for CARVYKTI®, statements related to Legend Biotech's ability toachieve operating profit; statements related to Legend Biotech’s ability to fund its operationsbeyond 2026 and Legend Biotech’s anticipated profitability excluding unrealized foreign Non-IFRS financial metrics This presentation refers to certain non-IFRS financial metr